Elevance Health Navigates Industry-Wide Headwinds: Buy the Dip?
In the first quarter of 2026, the financial markets witnessed a shifting landscape. While market breadth showed signs of improvement, geopolitical tensions in the Middle East and heavy concentration in high-valuation artificial intelligence (AI) stocks created a volatile environment for traditional value investors. Against this backdrop, Heartland Advisors released its Q1 2026 investor letter for the Heartland Opportunistic Value Equity Strategy. The strategy posted a solid return of 3.66%, outperforming its benchmark, the Russell 3000 Value Index, which gained 2.23% during the same period.
Despite this outperformance, some of the fund’s holdings experienced downward pressure. Notably, Elevance Health, Inc. (NYSE:ELV), a leading managed care giant, emerged as one of the primary detractors from the strategy’s Q1 performance. On June 26, 2026, ELV closed at $395.18 per share, representing a market capitalization of $85.81 billion. Over the short term, the company recorded a one-month return of -1.86%, though it managed a modest 1.60% gain over the past 52 weeks.
Understanding the Managed Care Selloff
The health insurance industry as a whole has battled severe operational headwinds. A confluence of factors has squeezed margins across the sector:
- Elevated Healthcare Utilization: Post-pandemic medical usage patterns have stabilized at higher-than-expected levels, driving up medical cost ratios (MCR) for insurers.
- Medical Inflation: Rising costs of clinical care, labor, and pharmaceuticals have escalated the expense base.
- Enrollment Disruptions: Policy shifts and redeterminations in Medicaid and the Affordable Care Act (ACA) exchanges have reshaped the risk pool and enrollment numbers.
These structural challenges have disproportionately harmed smaller regional competitors, which lack the capital buffer to absorb sustained losses. However, for industry behemoths like Elevance Health, this period of consolidation may actually pave the way for long-term dominance.
Valuation and Long-Term Outlook
According to Heartland Advisors, Elevance Health’s scale and robust balance sheet position it uniquely to exit this downturn with increased market share. Management has proactively utilized its capital structure to support equity value, engaging in consistent share buybacks. Currently, the stock trades at an attractive 30% discount to the Russell 3000 Value Index based on forward 12-month earnings estimates. Historically, ELV has traded on par with this benchmark, highlighting a significant valuation anomaly.
Institutional investors appear to be recognizing this entry point. Hedge fund sentiment has trended upward, with 87 hedge fund portfolios holding ELV at the end of the first quarter, up from 78 in the preceding quarter. While growth investors continue to chase high-multiple AI opportunities, value managers view Elevance’s discounted valuation as a resilient, cash-generative alternative with embedded earnings power ready to unlock as industry margins normalize.